Summary
Cyclacel Pharmaceuticals Inc (Cyclacel) is a biopharmaceutical company that develops oral therapies. The company develops small molecule drugs that target various phases of cell cycle control for the treatment of cancer and other serious diseases. Its products include sapacitabine, seliciclib, CDK inhibitor and PLK inhibitor. Cyclacel’s sapacitabine is the drug candidate used to treat the patients with acute myeloid leukemia. The company’s seliciclib is an orally available, cyclin dependent kinase inhibitor. It offers products for the treatment of anti-infective, autoimmune, cardiovascular, ophthalmic and other non-oncology indications. The company operates in the US and the UK. Cyclacel is headquartered in Berkeley Heights, New Jersey, the US.
Cyclacel Pharmaceuticals Inc (CYCC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Cyclacel Enters into Licensing Agreement with ManRos Therapeutics 11
Equity Offering 11
Cyclacel Pharma Raises USD15.2 Million in Public Offering of Units 11
Cyclacel Pharma Raises USD1 Million in Public Offering of Shares 13
Cyclacel Pharma Raises USD2.8 Million in Private Placement of Shares 14
Cyclacel Pharma to Raise up to USD8.35 Million in Private Placement of Shares 15
Cyclacel Pharma Raises USD10 Million in Public Offering of Shares 16
Cyclacel Pharma Completes Public Offering Of Shares For US$10 Million 17
Cyclacel Pharma Completes Public Offering Of Shares For US$20 Million 18
Cyclacel Pharma Completes Private Placement Of Shares For US$3 Million 20
Cyclacel Pharma Completes An Underwritten Public Offering Of US$10.4 Million 21
Asset Transactions 22
Celgene To Acquire Romidepsin Injection Patents From Cyclacel For US$5.5 Million 22
Cyclacel Pharmaceuticals Inc - Key Competitors 24
Key Employees 25
Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Financial Announcements 27
May 11, 2017: Cyclacel Pharmaceuticals Reports First Quarter 2017 Financial Results 27
Mar 28, 2017: Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results 29
Nov 14, 2016: Cyclacel Pharmaceuticals Reports 3rd Quarter 2016 Financial Results 31
Aug 10, 2016: Cyclacel Pharmaceuticals Reports 2nd Quarter 2016 Financial Results 33
May 11, 2016: Cyclacel Pharmaceuticals Reports First Quarter 2016 Financial Results 35
Mar 24, 2016: Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results 37
Corporate Communications 39
Jun 16, 2016: Cyclacel Regains Compliance With Nasdaq Continued Listing Requirements 39
Feb 05, 2016: Cyclacel Announces Receipt of Nasdaq Staff Determination; Company to Request Hearing 40
Clinical Trials 41
Apr 02, 2017: Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects in Lung Cancer by Engaging Anti-Metastatic Pathways 41
Mar 07, 2017: Cyclacels CDK Inhibitor CYC065 Causes Anaphase Catastrophe, a Novel Cancer-Specific Mechanism of Action, in Research Published in JNCI 43
Sep 06, 2016: Cyclacel's CYC065 Demonstrates Promising Activity in MYCN-Addicted Neuroblastoma in Preclinical Data Presented at Childhood Cancer 2016 44
Aug 02, 2016: Cyclacel CYC065 Demonstrates Promising Activity in Uterine Serous Carcinoma in Preclinical Data Published by Independent Academic Researchers 45
Apr 18, 2016: Cyclacel’s Second-Generation CDK2/9 Inhibitor, CYC065, is an Effective Inducer of Cell Death in B-cell Lymphoma and Synergizes With Bcl-2 or BET Inhibitors 46
Other Significant Developments 48
Jan 11, 2016: Cyclacel Reviews 2015 Achievements and Announces Key Business Objectives for 2016 48
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50
List of Tables
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Cyclacel Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Cyclacel Enters into Licensing Agreement with ManRos Therapeutics 11
Cyclacel Pharma Raises USD15.2 Million in Public Offering of Units 11
Cyclacel Pharma Raises USD1 Million in Public Offering of Shares 13
Cyclacel Pharma Raises USD2.8 Million in Private Placement of Shares 14
Cyclacel Pharma to Raise up to USD8.35 Million in Private Placement of Shares 15
Cyclacel Pharma Raises USD10 Million in Public Offering of Shares 16
Cyclacel Pharma Completes Public Offering Of Shares For US$10 Million 17
Cyclacel Pharma Completes Public Offering Of Shares For US$20 Million 18
Cyclacel Pharma Completes Private Placement Of Shares For US$3 Million 20
Cyclacel Pharma Completes An Underwritten Public Offering Of US$10.4 Million 21
Celgene To Acquire Romidepsin Injection Patents From Cyclacel For US$5.5 Million 22
Cyclacel Pharmaceuticals Inc, Key Competitors 24
Cyclacel Pharmaceuticals Inc, Key Employees 25
Cyclacel Pharmaceuticals Inc, Other Locations 26
Cyclacel Pharmaceuticals Inc, Subsidiaries 26List of Figures
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
